Skip to content

Prospective evaluation of embolization with absolute alcohol in the treatment of arteriovenous malformations

Prospective evaluation of embolization with absolute alcohol in the treatment of arteriovenous malformations

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015220
Enrollment
Unknown
Registered
2018-03-15
Start date
2018-03-14
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arteriovenous malformations

Interventions

Ethanol group:Embolization with absolute ethanol

Sponsors

Shanghai 9th People's Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 2-60 years; 2. With a typical clinical manifestation, coincidental imaging data including CT/MRI diagnosis by DSA; 3. No symptom threatening life such as massive bleeding or heart failure in recent period; No serious underlying systemic disease especially in immune system, respiratory system and circulatory system; 4. Not accepting any therapy in the last 3 months; 5. Ability and willingness to sign an inform consent form after fully understanding the therapeutic strategy and potential risks.

Exclusion criteria

Exclusion criteria: 1. Without a typical clinical manifestation, or having not exactly characters of medical imaging; 2. The nidus was closely connection with intracranial abnormal vessel lesion; 3. Having symptoms threatening life needing to manage immediately; 4. Serious underlying systemic disease requiring treatment until illness either completes therapy or achieves clinical stablility on therapy for at least 6 months before enrolled the study. The systemic diseases include insufficient pulmonary functions(COPD, pneumonia, pulmonary fibrosis and asthma), insufficient cardiac and hepatorenal functions, infection, hemorrhagic tendency, immunologic disease(SLE, urticaria, HIV); 5. Accepting any therapy in the last 3 months including operation or embolization; 6. Refusing to sign an inform consent form after fully understanding the therapeutic strategy and potential risks; 7. Other contraindications of embolization with ethanol including pregnancy, lactation or combining with some other drugs like antitumor drug.

Design outcomes

Primary

MeasureTime frame
Digital Subtraction Angiography (DSA);Clinical manisfestations;

Countries

China

Contacts

Public ContactXin-dong Fan

Shanghai 9th People's Hospital, Shanghai Jiaotong University, School of Medicine

fanxindong@aliyun.com+86 021-2965666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026